Ovarian Cancer Clinical Trial

Phase 1a/1b Study of STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Solid Tumors

Summary

This is a first-in-human, phase 1a/1b, multicenter, open-label, dose escalation study of STK-012 as monotherapy and in combination with pembrolizumab in patients with selected advanced solid tumors.

View Full Description

Full Description

The phase 1a portion of the study is standard 3+3 dose escalation design to evaluate STK-012 as monotherapy and in combination with pembrolizumab in patients with selected solid tumors who have progressed after standard of care treatments. The phase 1b portion of the study includes dose expansions to evaluate STK-012 as monotherapy and in combination with pembrolizumab at the recommended phase 2 dose (RP2D) in selected solid tumor types.

View Eligibility Criteria

Eligibility Criteria

Selected Inclusion Criteria

In dose-escalation (Phase 1a), patients must have selected tumor types and must have progressed after standard of care treatment, or be intolerant to treatment, or refused standard treatment
Available archived tumor tissue sample. In the setting where archival material is unavailable or unsuitable for use, the patient must consent and undergo fresh tumor biopsy. In some patients, a new pre-treatment and on-treatment tumor biopsy may be required.
Patients with central nervous system (CNS) metastases must have been treated and be asymptomatic.

Selected Exclusion Criteria:

Received systemic anti-cancer therapy within 3 weeks of the first dose of study treatment or small molecule kinase inhibitors within 6 elimination half-lives of the first dose of study treatment.
Received definitive radiotherapy within 2 weeks of the first dose of study treatment; or palliative radiotherapy (defined as < 2 weeks of radiotherapy to non-central nervous system [CNS] disease) within 1 week of the first dose of study treatment.
Received prior IL-2-based or IL-15-based cytokine therapy

Study is for people with:

Ovarian Cancer

Phase:

Phase 1

Estimated Enrollment:

202

Study ID:

NCT05098132

Recruitment Status:

Recruiting

Sponsor:

Synthekine

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 5 Locations for this study

See Locations Near You

Columbia University Irving Medical Center
New York New York, 10032, United States More Info
Nurse Navigator
Contact
212-342-5162
[email protected]
Memorial Sloan-Kettering Cancer Center
New York New York, 10065, United States More Info
Dmitriy Zamarin, MD
Contact
[email protected]
UPMC Hillman Cancer Center
Pittsburgh Pennsylvania, 15232, United States More Info
Sarah Behr
Contact
412-623-6028
[email protected]
Sarah Cannon Research Institute - Nashville
Nashville Tennessee, 37203, United States More Info
NEXT Virginia
Fairfax Virginia, 22031, United States More Info
Frances Gatlin, BSN, RN
Contact
210-580-9500
[email protected]

How clear is this clinincal trial information?

Study is for people with:

Ovarian Cancer

Phase:

Phase 1

Estimated Enrollment:

202

Study ID:

NCT05098132

Recruitment Status:

Recruiting

Sponsor:


Synthekine

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.